- The company believes that the study findings support its patented DehydraTECH(TM) system as being the world’s fastest-acting nicotine through oral absorption and a safer nicotine alternative for the 1.1 billion smokers of the world
- Plans for a human trial are in the design process, and Lexaria intends to use existing capital to execute the study
- The global nicotine pouch market is expected to grow to a total revenue of $21.84 billion by the end of 2027, a CAGR growth of 30.7% over the forecast period
A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) has announced the results of its recent NIC-A21-1 study on oral nicotine absorption, indicating that DehydraTECH(TM)-nicotine delivered by an oral pouch product format required two to four minutes to deliver the desired nicotine levels in blood plasma versus the 45 minutes with concentration-matched controls. Lexaria believes that the study’s findings support the world’s fastest-acting nicotine oral mucosal absorption market and offer a safer alternative for 1.1 billion smokers as a means of cessation (https://ibn.fm/gWi5h).
The key pharmacokinetic findings of the study support a statistically significant improvement in the delivery and peak levels of absorption. As a result of the performance of this study in animals, Lexaria’s next step is to progress to a larger investigation using human volunteers. The company will compare the DehydraTECH-nicotine pouches performance (using DehydraTECH-2.0) against existing brands like Zyn (Swedish Match) and ON! (Altria). The human study is currently in the design phase, and Lexaria intends to fund it with existing capital.
Lexaria is optimistic that the upcoming human trials will produce even more positive findings. Lexaria’s own research has demonstrated nicotine in the bloodstream in as little as 1.5-4.0 minutes after oral ingestion. These results align with the current dog study, in which DehydraTECH-nicotine required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.
“We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral pouch formulations in this study. Our technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction,” Lexaria CEO Chris Bunka said. “Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete.”
Smoking is one of the world’s most preventable health hazards. According to the World Health Organization (“WHO”), tobacco kills more than 8 million users each year – 7 million of which are direct tobacco users, whereas approximately 1.2 are those exposed to second-hand smoke. Without cessation support, only 4% of those who attempt to quit smoking are successful (https://ibn.fm/msDQn).
The performance of DehydraTECH in this study indicates that the technology is ideal for the oral nicotine pouch market, one of the fastest growing nicotine sectors in the world, and could help revolutionize the nicotine industry as a whole. The global nicotine pouch market reached a value of $2.33 billion in 2020 and is expected to grow at a high CAGR (30.7%) during the forecast period of 2021-2027, to reach approximately $21.84 billion in revenue by the end of 2027 (https://ibn.fm/XXgFM).
The NIC-A21-1 study was performed in a leading, independent testing laboratory using 40 anesthetized male beagle dogs, divided into four groups of ten. All of the beagles used in the study were attended to with the highest levels of care, tolerated the DehydraTECH pouches well, and were returned to full health at the conclusion of the study.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
